Marc A Riedl

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism
    Marc Riedl
    From the Section of Clinical Immunology and Allergy, UCLA David Geffen School of Medicine, Los Angeles, CA
    World Allergy Organ J 3:S34-8. 2010
  2. ncbi request reprint Creating a comprehensive treatment plan for hereditary angioedema
    Marc A Riedl
    Division of Rheumatology, Allergy and Immunology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA Electronic address
    Immunol Allergy Clin North Am 33:471-85. 2013
  3. pmc HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation
    Guillermina J Baay-Guzman
    Hospital Infantil de Mexico, Federico Gomez, Unidad de Investigación en Enfermedades Oncológicas, Dr, Marquez No 262, Col, Doctores, Delegacion Cuahutemos, Mexico City CP 06720, Mexico
    Respir Res 13:60. 2012
  4. doi request reprint Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study
    Marc A Riedl
    University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
    Ann Allergy Asthma Immunol 110:295-9. 2013
  5. doi request reprint Hereditary angioedema therapies in the United States: movement toward an international treatment consensus
    Marc Riedl
    Section of Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 1680, USA
    Clin Ther 34:623-30. 2012
  6. doi request reprint Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial
    Marc A Riedl
    Department of Clinical Immunology and Allergy, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA
    Ann Allergy Asthma Immunol 108:49-53. 2012
  7. doi request reprint Update on the acute treatment of hereditary angioedema
    Marc A Riedl
    Department of Medicine, University of California Los Angeles, 90095, USA
    Allergy Asthma Proc 32:11-6. 2011
  8. doi request reprint Response time for ecallantide treatment of acute hereditary angioedema attacks
    Marc Riedl
    University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
    Ann Allergy Asthma Immunol 105:430-436.e2. 2010
  9. pmc Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway
    Marc A Riedl
    The Hart and Louis Laboratory, Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Immunol 130:244-51. 2009
  10. ncbi request reprint The effect of air pollution on asthma and allergy
    Marc A Riedl
    Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Curr Allergy Asthma Rep 8:139-46. 2008

Collaborators

Detail Information

Publications17

  1. pmc Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism
    Marc Riedl
    From the Section of Clinical Immunology and Allergy, UCLA David Geffen School of Medicine, Los Angeles, CA
    World Allergy Organ J 3:S34-8. 2010
    ..Optimization of HAE therapy will require further integration of new therapies into the current treatment paradigm...
  2. ncbi request reprint Creating a comprehensive treatment plan for hereditary angioedema
    Marc A Riedl
    Division of Rheumatology, Allergy and Immunology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA Electronic address
    Immunol Allergy Clin North Am 33:471-85. 2013
    ..This review summarizes the current evidence for best practices in HAE management, and suggests practical steps toward developing a comprehensive treatment plan. ..
  3. pmc HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation
    Guillermina J Baay-Guzman
    Hospital Infantil de Mexico, Federico Gomez, Unidad de Investigación en Enfermedades Oncológicas, Dr, Marquez No 262, Col, Doctores, Delegacion Cuahutemos, Mexico City CP 06720, Mexico
    Respir Res 13:60. 2012
    ..We hypothesized that the expression of HIF-1 and CCL2 may be correlated and that the expression of CCL2 may be under the regulation of HIF-1. Several lines of evidence are presented to support this hypothesis...
  4. doi request reprint Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study
    Marc A Riedl
    University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
    Ann Allergy Asthma Immunol 110:295-9. 2013
    ..The efficacy of recombinant human C1 inhibitor (rhC1INH) for the treatment of patients with acute hereditary angioedema (HAE) attacks has been demonstrated in 2 randomized, double-blind, placebo-controlled studies...
  5. doi request reprint Hereditary angioedema therapies in the United States: movement toward an international treatment consensus
    Marc Riedl
    Section of Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 1680, USA
    Clin Ther 34:623-30. 2012
    ..Pharmacologic developments in HAE treatment have culminated in the recent introduction of 4 new HAE-specific therapies in the United States...
  6. doi request reprint Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial
    Marc A Riedl
    Department of Clinical Immunology and Allergy, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA
    Ann Allergy Asthma Immunol 108:49-53. 2012
    ..Hereditary angioedema (HAE) is a rare disease caused by C1INH gene mutations, which leads to a deficiency or dysfunction of C1 inhibitor (C1 INH), resulting in recurrent episodes of severe and potentially life-threatening edema...
  7. doi request reprint Update on the acute treatment of hereditary angioedema
    Marc A Riedl
    Department of Medicine, University of California Los Angeles, 90095, USA
    Allergy Asthma Proc 32:11-6. 2011
    ..Clinicians should consider a number of patient- and medication-specific factors when designing individualized treatment plans for HAE patients...
  8. doi request reprint Response time for ecallantide treatment of acute hereditary angioedema attacks
    Marc Riedl
    University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1680, USA
    Ann Allergy Asthma Immunol 105:430-436.e2. 2010
    ..Ecallantide is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks...
  9. pmc Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway
    Marc A Riedl
    The Hart and Louis Laboratory, Clinical Immunology and Allergy, Department of Medicine, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Immunol 130:244-51. 2009
    ..Endogenous Phase II enzymes abrogate oxidative stress through the scavenging of reactive oxygen species and metabolism of reactive chemicals...
  10. ncbi request reprint The effect of air pollution on asthma and allergy
    Marc A Riedl
    Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Curr Allergy Asthma Rep 8:139-46. 2008
    ....
  11. doi request reprint Importance of oxidative stress in the pathogenesis and treatment of asthma
    Marc A Riedl
    Section of Clinical Immunology and Allergy, Division of Pulmonary and Critical Care Medicine, UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA
    Curr Opin Allergy Clin Immunol 8:49-56. 2008
    ..The purpose of the current review is to summarize recent evidence demonstrating the important role of oxidative stress in asthma pathogenesis. The therapeutic implications of these findings will be presented...
  12. ncbi request reprint Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen
    Marc A Riedl
    Hart and Louis Lyon Laboratory, Division of Clinical Immunology and Allergy, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
    J Immunol 174:7440-5. 2005
    ..Whether this immune response represents durable allergic tolerance is not yet known. Studies investigating the molecular mechanisms of this non-IgE response may be useful in developing therapy to prevent allergic sensitization...
  13. doi request reprint Current medical management of hereditary angioedema: results from a large survey of US physicians
    Marc Riedl
    Section of Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, 90095, USA
    Ann Allergy Asthma Immunol 106:316-322.e4. 2011
    ..There are no known surveys of US physicians' knowledge and experience regarding the epidemiology, diagnosis, and management of HAE...
  14. ncbi request reprint Adverse drug reactions: types and treatment options
    Marc A Riedl
    University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Am Fam Physician 68:1781-90. 2003
    ..Reactions to radiocontrast media can be limited by pretreatment with prednisone, diphenhydramine, and either ephedrine or a histamine H2-receptor antagonist...
  15. doi request reprint Novel antioxidant approaches to the treatment of upper airway inflammation
    Melinda Braskett
    Department of Medicine, University of California, Los Angeles, USA
    Curr Opin Allergy Clin Immunol 10:34-41. 2010
    ..This review summarizes recent investigations of novel antioxidant agents for upper airway inflammation, with selected studies focused on lower airway disease as additional candidate therapeutics...
  16. doi request reprint Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema
    Marc A Riedl
    1Department of Clinical Immunology and Allergy, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA
    Am J Rhinol Allergy 27:517-21. 2013
    ..The objective of this analysis was to evaluate the effectiveness and tolerability of C1 INH-nf when used for the treatment of laryngeal attacks...
  17. doi request reprint HAE update: special considerations in the female patient with hereditary angioedema
    Bob Geng
    Section of Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
    Allergy Asthma Proc 34:13-8. 2013
    ..Finally, this review will provide an overview of the more recently characterized HAE with normal C1-INH (HAE type III) that predominantly affects women and is in some cases associated with factor XII gene mutations...